SEK1338.2m market cap
SEK18.38 last close
Cantargia is a clinical stage biotechnology company based in Sweden, established in 2009 and listed on Nasdaq Stockholm main market. It is developing two antibodies against IL1RAP, nidanilimab (CAN04) and CANxx. Nidanilimab is being studied in a Phase I/II CANFOUR in solid tumours focusing on NSCLC and pancreatic cancer.
Investment summary
Cantargia is developing two antibodies against IL1RAP: Nidanilimab (CAN04) and CANxx. Nidanilimab is currently being studied in a Phase I/II CANFOUR trial where the Phase I part focuses on several solid tumours, and the Phase II part focuses on NSCLC and pancreatic cancer. So far, Nidanilimab was found to be safe and well tolerated in the Phase I part of the study, and the first patient has been treated in the Phase II part. Nidanilimab has a dual mechanism of action: inhibition of IL-1 signaling and antibody-dependent cellular cytotoxicity (ADCC). Novartis is conducting three Phase III trials in NSCLC with canakinumab (IL-1beta antibody) following some intriguing results from its six-year Phase III cardiovascular outcomes study in heart attack patients. Cantargia has recently raised SEK106m in a directed share issue.
Y/E Dec |
Revenue (SEKm) |
EBITDA (SEKm) |
PBT (SEKm) |
EPS (fd) (öre) |
P/E (x) |
P/CF (x) |
|---|---|---|---|---|---|---|
| 2017A | 0.0 | (60.0) | (60.3) | (186.00) | N/A | N/A |
| 2018A | 0.0 | (93.3) | (91.2) | (137.73) | N/A | N/A |
| 2019E | 0.0 | (94.9) | (94.6) | (142.88) | N/A | N/A |
| 2020E | 0.0 | (117.8) | (117.8) | (178.01) | N/A | N/A |
| Last updated on 20/05/2019 | ||||||
Industry outlook
Increasing the understanding of inflammation in malignant process now includes findings that cytokines are not only produced by the immune cells, but also cancer itself could produce certain cytokines and the associated receptors to escape from the immune response. Therefore, cytokines represent potentially promising class of targets in cancer management.
Last updated on 20/05/2019
Sector |
|---|
| Healthcare |
Share price graph
Balance sheet |
|
|---|---|
| Forecast net cash (SEKm) | 72.3 |
| Forecast gearing ratio (%) | N/A |
Price performance
% |
1m |
3m |
12m |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||||||
| *% relative to local index | |||||||||||||||
Key management |
|
|---|---|
| Goran Forsberg | CEO |
You may also be interested in…
- 4SC
- Acacia Pharma
- Acarix
- ADL Bionatur Solutions
- Adocia
- ASIT biotech
- Basilea Pharmaceutica
- BioPorto Diagnostics
- Bonesupport
- Brighter
- Carmat
- Celyad
- Deinove
- Formycon
- Herantis Pharma
- Hybrigenics
- Immunicum
- Immunovia
- Kiadis Pharma
- Laboratorios Farmacéuticos ROVI
- MagForce
- Medigene
- Mologen
- Nanobiotix
- NeuroVive Pharmaceutical
- Newron Pharmaceuticals
- Nuevolution
- Oncology Venture
- Onxeo
- Orexo
- Oryzon Genomics
- OSE Immunotherapeutics
- Paion
- Photocure
- Pixium Vision
- Probiodrug
- Quantum Genomics
- Rovi
- Selvita
- Targovax
- Transgene
- TxCell
- Xbrane Biopharma